 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AL01211 / AceLink Therap
P1 data, Journal: Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non-brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease. (Pubmed Central) - Jun 1, 2024
Increasing exposure inversely correlated with a decrease in GSL with plasma glucosylceramide and globotriacylceramide reduction from baseline levels, reaching 78% and 52% by day 14, respectively. AL01211 was generally well-tolerated with no AL01211 associated serious adverse events, thus supporting its further clinical development.
- || AL01211 / AceLink Therap
New P2 trial: Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease (clinicaltrials.gov) - Nov 1, 2023
P2, N=16, Recruiting, Sponsor: AceLink Therapeutics, Inc.
- ||| AL01211 / AceLink Therap
Trial completion: To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers (clinicaltrials.gov) - Oct 14, 2022
P1, N=69, Completed, Sponsor: AceLink Therapeutics, Inc.
AL01211 was generally well-tolerated with no AL01211 associated serious adverse events, thus supporting its further clinical development. Active, not recruiting --> Completed
- || AL01211 / AceLink Therap
Enrollment closed: To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers (clinicaltrials.gov) - May 20, 2022
P1, N=80, Active, not recruiting, Sponsor: AceLink Therapeutics, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| AL01211 / AceLink Therap
Enrollment open: To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers (clinicaltrials.gov) - Aug 3, 2021
P1, N=98, Recruiting, Sponsor: AceLink Therapeutics, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| AL01211 / AceLink Therap
New P1 trial: To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers (clinicaltrials.gov) - Jun 1, 2021
P1, N=98, Not yet recruiting, Sponsor: AceLink Therapeutics, Inc.